Entreprise · 08/08/20111 min de lecture
Prospective Grant of Exclusive License: Use of PKM2 Activators for the Treatment of Cancer
Traduction automatique locale · Langue originale de la source
Résumé
This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the inventions embodied in U.S. Provisional Patent Application No. 61/104,091, entitled "Activators of Human Pyruvate Kinase," filed October 9, 2008, now abandoned [HHS Ref. No. E-326-2008/0-US-01]; PCT/US2009/60237 Application entitled "Small Molecule Activators of Pyruvate Kinase," filed October 9, 2009, now abandoned [HHS Ref. No. E-326-2008/0-PCT-02]; EP Application No. 09740795.1, entitled "Small Molecule Activators of Pyruvate Kinase," filed October 9, 2009 [HHS Ref. No. E-326-2008/0-EP-05]; U.S. Non- Provisional Application No. 13/123,297, entitled "Small Molecule Activators of Pyruvate Kinase," filed April 8, 2011 [HHS Ref. No. E-326-2008/0-US-07]; Australian National Application No. 2009303335, entitled "Small Molecule Activators of Pyruvate Kinase," filed October 9, 2010 [HHS Ref. No. E-326-2008/0-AU-03]; Canadian National Application, entitled "Small Molecule Activators of Pyruvate Kinase," filing date pending [HHS Ref. No. E-326-2008/0-CA-04